Sign in
Taking peopleNo phase

Skin and blood markers to predict gestational diabetes and large babies

Compares new sugar-damage markers with HbA1c in pregnant women for predicting gestational diabetes.

Key facts

Who runs it
University Hospital, Bordeaux
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
Status
Recruiting
People taking part
800 people, planned
Started
18 Dec 2023
Expected to end
Sept 2028
Type of study
Interventional
Treatments tested
  • Pregnant women
Record updated
15 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women, with or without risk factors for diabetes in pregnancy, before 28 weeks of pregnancy. It tests blood and skin markers of sugar damage to predict diabetes in pregnancy and a large baby.

Age
18 years to 99 years
Sex
Pregnant women
Disease stage
Pregnancy with one baby, at less than 28 weeks since the last period. A twin pregnancy reduced to one baby before 14 weeks can also join.
Earlier treatment
People who had weight-loss (bariatric) surgery cannot join.

Main reasons for not taking part

  • 28 weeks of pregnancy or more
  • Pregnancy with more than one baby
  • Diabetes known before the pregnancy
  • Past weight-loss (bariatric) surgery
  • Planned birth in a maternity unit not taking part in the study

This trial only enrols pregnant participants. The registry sentence this rests on: Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14 weeks of amenorrhea)

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Singleton pregnancy (or twin pregnancy reduced spontaneously or medically before 14 weeks of amenorrhea)
  • Gestational age at inclusion <28 weeks of amenorrhea
  • Participant affiliated with or beneficiary of a social security scheme
  • Collection of patient consent

Who cannot take part

  • Known diabetes prior to pregnancy
  • History of bariatric surgery
  • Gestational age at inclusion ≥ 28 weeks of amenorrhea
  • Multiple pregnancy
  • Expected delivery in another maternity unit not participating in the study
  • Person deprived of liberty by judicial or administrative decision
  • Guardianship or curatorship
  • Participant not affiliated or not benefiting from a social security scheme

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gestational diabetes mellitus (GDM) increases the risk of macrosomia and other adverse pregnancy outcomes. Screening strategies are debated: universal vs. selective, and macrosomia may begin before the time of screening, suggesting that glycation markers may have an interest. The objective of this trail is to compare novel markers: skin autofluorescence and glycated albumin, to HbA1c (reference) as predictors of GDM, macrosomia and other adverse outcomes, in pregnant women.

The group in the trial

  • Pregnant womenTreatment being tested

    Pregnant women, with gestational age at inclusion \<28 weeks of amenorrhea, with or without risk factors for GDM will be included in the first consultation at the Maternity Hospital (Bordeaux University Hospital). Determination of glycation markers (HbA1c, glycated albumin, and skin autofluorescence).

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
New Markers of Glycation to Predict Gestational Diabetes Mellitus and Macrosomia.
Plain-language title
Skin and blood markers to predict gestational diabetes and large babiesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT06048510, who can take part
Record updated
15 January 2026